ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 19,860 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $71.70, for a total transaction of $1,423,962.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Meridian Venture Partners Ii L also recently made the following trade(s):
- On Tuesday, August 13th, Meridian Venture Partners Ii L sold 61,697 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.64, for a total transaction of $4,419,973.08.
ANI Pharmaceuticals stock opened at $67.09 on Friday. The firm’s fifty day moving average price is $80.45 and its 200-day moving average price is $70.60. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The stock has a market cap of $847.24 million, a P/E ratio of 14.55 and a beta of 2.17. ANI Pharmaceuticals Inc has a fifty-two week low of $36.92 and a fifty-two week high of $86.96.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.26. The firm had revenue of $54.36 million for the quarter, compared to analysts’ expectations of $55.20 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the company posted $1.13 EPS. On average, analysts predict that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current year.
ANIP has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 target price (up from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $89.00.
Several institutional investors have recently bought and sold shares of ANIP. Tower Research Capital LLC TRC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $32,000. Financial Gravity Wealth Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $54,000. Quantamental Technologies LLC raised its position in shares of ANI Pharmaceuticals by 169.4% during the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 542 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 237.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 559 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 64.22% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: Insider Trading
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.